Relative Bioavailability of Two Orally Administered CBD Formulations in Healthy Male Adults

NCT06574100

Status	RECRUITING
Phase	Phase 1
Sponsor	University of Saskatchewan
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (5)

- Age 18 - 35 years old
- Clinical labs within the stated normal range of the Royal University Hospital Test Centre, or values outside the stated normal range that are not of clinical significance as determined by the qualified investigator.
- No clinically significant disease on medical history or clinically significant findings on physical examination including vital signs as determined by the qualified investigator.
- Ability to stay in the clinic trial unit for 13 hours on the day of each single oral dose.
- Ability to return for blood draws in the subsequent days.

Exclusion (16)

- History or presence of significant gastrointestinal, liver or kidney disease or any other condition known to interfere with drug pharmacokinetics including bioavailability or increase risk of adverse effects.
- History or presence of serious cardiovascular disease, such as ischaemic heart disease, arrhythmias, poorly controlled hypertension or severe heart failure
- Males whose partners are trying to conceive (i.e. male subjects intending to start a family during the study period)
- Lack of medically acceptable contraception by participants whose female partners have childbearing potential for the duration of the study.
- Personal or family history of schizophrenia or any other psychotic disorder

... and 11 more (see full listing online)

Locations (1 total)

University of Saskatchewan, Saskatoon, Saskatchewan, Canada